Publication: Labeling of adult stem cells for
in vivo-application in the human heart
Authors
Wiehe, J.M.I. ; Zimmermann, O. ; Greiner, J. ; Homann, J.M. ; Wiesneth, M. ; Hombach, V. ; Torzewski, J.
item.page.secondaryauthor
item.page.director
Publisher
Murcia : F. Hernández
publication.page.editor
publication.page.department
DOI
item.page.type
info:eu-repo/semantics/article
Description
Abstract
Tissue regeneration with human
hematopoietic or mesenchymal stem cells has become a
fashionable research topic. In cardiology, intracoronary
injection of adult stem cells has already been used for
the treatment of human myocardial infarction and
ischemic cardiomyopathy. The experimental background
of such therapies, however, i.e. the potential of adult
stem cells to regenerate myocardium through
“transdifferentiation” of hematopoietic or mesenchymal
stem cells into cardiomyocytes described in animal
models, has recently been challenged by other
experimental data. Nonetheless, clinical trials are
continuing. This may be due to the fact that, in openlabeled
pilot trials, a benefit of intracoronary injection of
adult stem cells for the treatment of myocardial
infarction has been described. As pilot trials may
overemphasize the beneficial effects of intracoronary
injection of bone marrow stem cells, controled doubleblinded
randomised multicenter studies are warranted.
Furthermore, a careful characterization of the cells
involved in the proposed cardiac repair as well as in
vivo-monitoring of such cells following intracoronary
injection in humans might help to answer many essential
questions linked to this important research topic. The
latter requires biocompatible labeling. This review
focusses on the technologies available for stem cell
labeling and summarizes the arguments and contraarguments
to use these labeling technologies for
application in humans.
publication.page.subject
Citation
item.page.embargo
Ir a Estadísticas
Sin licencia Creative Commons.